Another study has reported that binding of tumor-derived VEGF to VEGFR on CD34+ bone marrow progenitor cells reduces the differentiation of these cells into dendritic cells, thus limiting the efficacy of GM-CSF-related immunotherapy (51). This evidence concerns the gene CSF2 and neoplasm.